References: Aramaki O, Shirasugi N, Takayama T, Shimazu M, Kitajima M, Ikeda Y, Azuma M, Okumura K, Yagita H, Niimi M. 2004. Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation. Jan 15;77(1):6-12.
Tseng SY, Otsuji M, et al. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193(7): 839-46.
Carter L, Fouser L, et al. 2002. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32(3): 634-43.
Latchman Y, Wood CR, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3): 261-8.
Yamazaki T, Akiba H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002 Nov 15;169(10):5538-45.
Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, Fukushima T, Akiba H, Yagita H, Okumura K, Machida U, Iwai H, Azuma M, Chen L, Watanabe M. 2003. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 171(8):4156-63.
Mohammed Javeed I. Ansari, Alan D. Salama, Tanuja Chitnis, R. Neal Smith, Hideo Yagita, Hisaya Akiba, Tomohide Yamazaki, Miyuki Azuma, Hideyuki Iwai, Samia J. Khoury, Hugh Auchincloss, Jr. and Mohamed H. Sayegh. 2003. The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. J Exp Med 198 (1): 63-69.
Tanaka K., M. Albin et al. 2007. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 179(8):5204-5210. (FA, PubMed)